[Change of serum soluble vascular cell adhesion molecule-1 in patients with acute cerebral infarction and its clinical significance].

The aim of this study is to characterize the pattern of release of soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients with acute cerebral infarction. The level of serum sVCAM-1 was measured serially with two-layer antibody sandwich enzyme-linked immunosorbent assay (ELISA) in 89 patients with acute cerebral infarction, 43 patients with cerebral haemorrhage and 30 normal controls. It is shown that the level of serum sVCAM-1 in patients with cerebral infarction 24 hours after the onset was higher than that in patients with cerebral haemorrhage and normal controls (P < 0.01). The level of serum sVCAM-1 was significantly higher in the patients with large cerebral infarction than that in patients with medium and small cerebral infarctions (P < 0.01). The level of serum sVCAM-1 in patients with cerebral infarction increased from 24 hours to 7 days and decreased from 7 days to 14 days, but it was still higher than that in patients with cerebral haemorrhage and normal controls on the 14th day. The level of serum sVCAM-1 was higher in patients with infection as compared with those without. These findings suggested that sVCAM-1 is closely related to the development of acute cerebral infarction. It is essential to have further study on the change of serumsVCAM-1 in cerebral infarction.